(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
03 March 2022 (03.03.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/043755 A3

(51) International Patent Classification:
C07C 235/54 (2006.01) *A61P 9/10* (2006.01)
A61P 9/04 (2006.01)

(21) International Application Number:
PCT/IB2021/000594

(22) International Filing Date:
31 August 2021 (31.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/072,848 31 August 2020 (31.08.2020) US
63/227,279 29 July 2021 (29.07.2021) US

(71) Applicant: **SANOFI** [FR/FR]; 54 Rue La Boetie, 75008 Paris (FR).

(72) Inventors: **PERNERSTORFER, Josef**; 54 Rue La Boetie, 75008 Paris (FR). **ROCCO, William**; 54 Rue La Boetie, 75008 Paris (FR). **BRITTAIN, Jason**; C/o Horizon Therapeutics Ireland Dac, Connaught House, 1st Floor, 1 Burlington Road, Dublin, D04 C5Y6 (IE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
21 April 2022 (21.04.2022)

WO 2022/043755 A3

(54) Title: CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING

(57) Abstract: Described herein are crystalline forms of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3- dihydro-1H-indene-2-carboxylic acid and methods of makingthe same. Such forms of 2-(4- methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid are useful in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with an EDG-2 receptor antagonist compound.